| 靶点: |
PIM1 0.24 nM (IC50);PIM2 30 nM (IC50);PIM3 0.12 nM (IC50) |
| 体内研究: |
Uzansertib phosphate (25-100 mg/kg; PO; twice a day; for 15 days) inhibits tumor growth in a dose-dependent manner in mice bearing MOLM-16 (AML) or KMS-12-BM (MM) . Uzansertib phosphate demonstrates a dose-dependent inhibition of BAD phosphorylation relative to vehicle at 4 hours post dose (MOLM-16 tumors, IC50=70 nM; KMS-12-BM tumors, IC50=145 nM) . |
| 溶解性: |
DMSO: 5 mg/mL |
| 保存条件: |
-80℃(运输条件:冰袋低温运输) |
| 配置溶液浓度参考: |
|
1mg |
5mg |
10mg |
| 1 mM |
1.635 ml |
8.177 ml |
16.353 ml |
| 5 mM |
0.327 ml |
1.635 ml |
3.271 ml |
| 10 mM |
0.164 ml |
0.818 ml |
1.635 ml |
| 50 mM |
0.033 ml |
0.164 ml |
0.327 ml |
|
| 注意: |
部分产品我司仅能提供部分信息,我司不保证所提供信息的权威性,仅供客户参考交流研究之用。 |